Mechanistic Approach to Immunity and Immunotherapy of Alzheimer’s Disease: A Review DOI

Md. Rubiath Islam,

Md. Afser Rabbi,

Tanbir Hossain

и другие.

ACS Chemical Neuroscience, Год журнала: 2024, Номер unknown

Опубликована: Авг. 22, 2024

Alzheimer's disease (AD) is a debilitating neurodegenerative condition characterized by progressive cognitive decline and memory loss, affecting millions of people worldwide. Traditional treatments, such as cholinesterase inhibitors NMDA receptor antagonists, offer limited symptomatic relief without addressing the underlying mechanisms. These limitations have driven development more potent effective therapies. Recent advances in immunotherapy present promising avenues for AD treatment. Immunotherapy strategies, including both active passive approaches, harness immune system to target mitigate AD-related pathology. Active stimulates patient's response produce antibodies against AD-specific antigens, while involves administering preformed or cells that specifically amyloid-β (Aβ) tau proteins. Monoclonal antibodies, aducanumab lecanemab, shown potential reducing Aβ plaques slowing clinical trials, despite challenges related adverse responses need precise targeting. This comprehensive review explores role AD, evaluates current successes immunotherapeutic discusses future directions enhancing treatment efficacy.

Язык: Английский

Mechanistic Approach to Immunity and Immunotherapy of Alzheimer’s Disease: A Review DOI

Md. Rubiath Islam,

Md. Afser Rabbi,

Tanbir Hossain

и другие.

ACS Chemical Neuroscience, Год журнала: 2024, Номер unknown

Опубликована: Авг. 22, 2024

Alzheimer's disease (AD) is a debilitating neurodegenerative condition characterized by progressive cognitive decline and memory loss, affecting millions of people worldwide. Traditional treatments, such as cholinesterase inhibitors NMDA receptor antagonists, offer limited symptomatic relief without addressing the underlying mechanisms. These limitations have driven development more potent effective therapies. Recent advances in immunotherapy present promising avenues for AD treatment. Immunotherapy strategies, including both active passive approaches, harness immune system to target mitigate AD-related pathology. Active stimulates patient's response produce antibodies against AD-specific antigens, while involves administering preformed or cells that specifically amyloid-β (Aβ) tau proteins. Monoclonal antibodies, aducanumab lecanemab, shown potential reducing Aβ plaques slowing clinical trials, despite challenges related adverse responses need precise targeting. This comprehensive review explores role AD, evaluates current successes immunotherapeutic discusses future directions enhancing treatment efficacy.

Язык: Английский

Процитировано

3